Niraparib CAS No.1038915-60-4 Pharmaceutical Intermediates

Product name	Niraparib
CAS No.	1038915-60-4
EINECS	/
Formula	C19H20N4O
Molecular Weight	320.39
Appearance	Light yellow powder
Purity	≥98%
Type	Pharmaceutical Intermediates

- High Purity: Niraparib is manufactured with exceptional purity to ensure optimal efficacy and safety for patients.

- Integrated Production and Trading: Our company combines manufacturing and trading to provide customers with a seamless supply chain.

- Advanced Formula: Niraparib is designed for targeted therapy and can effectively inhibit the growth of cancer cells.

- Pharmaceutical Grade: Meets international pharmaceutical standards, ensuring reliability and quality.

- Global Presence: We serve customers worldwide with competitive pricing and timely delivery.

- Oncology expertise: Our team has extensive experience in the pharmaceutical industry, especially in oncology.

product details

Product details

introduce

Niraparib is a potent oral poly (ADP-ribose) polymerase (PARP) inhibitor, primarily used to treat ovarian cancer. As a member of the PARP inhibitor class of drugs, niraparib plays a vital role in the treatment of cancers associated with BRCA mutations. Its mechanism of action involves selectively targeting cancer cells, leading to cancer cell death while sparing normal cells, which has significant advantages in cancer treatment.

Physical and chemical properties

- Niraparib has unique physical and chemical properties that contribute to its effectiveness as a therapeutic agent.

- Molecular formula: C19H20N4O

- Molecular weight: 320.39 g/mol

- Appearance: Niraparib is usually a light yellow powder.

- Solubility: It is soluble in organic solvents such as DMSO and methanol and has limited solubility in water, which is critical for its formulation in oral dosage forms.

- Stability: Niraparib exhibits good stability under recommended storage conditions, ensuring a longer shelf life and maintaining its therapeutic efficacy.

advantage

- Targeted therapy: By specifically inhibiting PARP, niraparib can effectively target cancer cells with DNA repair defects, thereby increasing cancer cell death.

- Oral: The convenience of oral administration improves patient compliance compared to intravenous treatment.

- Proven Effective: Clinical trials have shown that niraparib can effectively prolong the progression-free survival of patients with recurrent ovarian cancer.

- Minimal side effects: Compared with traditional chemotherapy, niraparib has fewer side effects, allowing patients to maintain a better quality of life during treatment.

- Multiple Applications: While niraparib is primarily used to treat ovarian cancer, ongoing research is exploring its potential in treating other cancers, including breast and prostate cancer.

Uses in the pharmaceutical industry

Niraparib is used primarily in the pharmaceutical industry to treat various cancers, especially those associated with BRCA mutations. Its use is not limited to ovarian cancer, and its efficacy in other malignancies is currently being studied.

In conclusion,Niraparib represents a significant advancement in cancer treatment, providing a targeted therapy with proven efficacy and a favorable safety profile. Our company is committed to providing high-quality Niraparib, backed by our expertise in the pharmaceutical industry and a strong supply chain. By choosing Niraparib, you are not only investing in cutting-edge cancer treatment, but also working with a reliable manufacturer committed to improving patient outcomes around the world.